When assessing treatments for flu and cold symptoms, it is important for the pharmacist to consider not only the patient’s current medication regimen, but also other OTCs and disease states.
With the ongoing cold and flu season combined with spiking COVID-19 cases, patients are increasingly reaching out to pharmacists asking for OTC recommendations. Symptoms such as a stuffy nose or sore throat are common and can typically be treated with OTC products.
Some examples of drug classes these products typically contain are cough suppressants, antipyretic, antihistamines, nasal decongestants, or a combination of these products to provide multi-symptom relief. Before making recommendations there are a few things a pharmacist should verify to provide the best care.
When first beginning an encounter with a patient, it is important to determine which products can help with symptom management. When assessing possible treatments, it is important for the pharmacist to consider not only the patient’s current medication treatments, but also other OTCs and disease states.
It is also important to counsel patients on the risk of duplicate therapy to avoid exacerbating possible adverse effects. After gathering information regarding the patient’s current medications and allergies, the pharmacist can then consider OTC options.
It is important to note that many of these products are sold as morning and nighttime due to the ingredients contained. Morning formulations typically contains a mucus expectorant, such as guaifenesin, to help break up mucus.
This is opposed to nighttime formulations which tend to exclude a nasal decongestant due to the stimulating effects that may cause difficulty falling asleep. Instead, antihistamines, specifically first generation which have the greatest risk of sedation are used at bedtime to help promote sleep.
Examples of commonly used ingredients:
Note: if symptoms worsen or last longer than 10 days advise the patient to speak to a physician.
Other helpful interventions include:
Listed in below are some key points to keep in mind when recommending products for patients that are considered a special population or if there are certain disease states present.
About the Authors
Tiffany DiMaggio is a PharmD Candidate at Duquesne University in Pittsburgh, PA, anticipated to graduate in Spring 2022.
Jonathan Ogurchak, PharmD, CSP, is the CEO and cofounder of STACK, a pharmacy information management platform, and serves as preceptor for a virtual Advanced Pharmacy Practice Experiential Rotation for specialty pharmacy, during which this article was composed.